Sofia® 2 SARS Antigen FIA

Contains: (25) Individually Packaged Test Cassettes, (25) Reagent Tubes, (25) Ampoules of Reagent Solution, (25) Sterile Nasal Swabs, (25) X 120 µL Fixed Volume Pipettes, Positive Control Swab, Negative Control Swab, Package Insert, Quick Reference Instructions, QC Card

The Sofia® 2 SARS Antigen FIA (QUI-20374) is a highly sensitive and rapid diagnostic test designed for the detection of SARS-CoV-2, the virus responsible for COVID-19. Utilizing advanced fluorescence immunoassay (FIA) technology, this test provides reliable and accurate results for identifying active infections, enabling timely diagnosis and management of COVID-19 cases.

Manufactured by Quidel, a leader in diagnostic testing, the Sofia® 2 SARS Antigen FIA offers a streamlined and user-friendly approach to COVID-19 testing. The test is intended for use in various healthcare settings, including clinics, hospitals, and point-of-care environments, where quick and accurate detection of SARS-CoV-2 is essential.

Key Features:

• Advanced Fluorescence Immunoassay (FIA) Technology: The Sofia® 2 SARS Antigen FIA employs sophisticated fluorescence detection to identify SARS-CoV-2 antigens with high sensitivity and specificity. This technology enhances the accuracy of test results and reduces the likelihood of false positives and false negatives.
• Rapid Results: The test delivers results in as little as 15 minutes, allowing for swift diagnosis and decision-making. The quick turnaround time is particularly beneficial for high-throughput testing environments and urgent patient care situations.
• Ease of Use: Designed for simplicity, the Sofia® 2 SARS Antigen FIA is easy to perform and interpret. The test involves a straightforward procedure with minimal steps, making it accessible for healthcare providers with varying levels of experience.
• High Sensitivity and Specificity: The test is engineered to detect low levels of SARS-CoV-2 antigens, ensuring reliable identification of active infections. Its high specificity helps to minimize the risk of cross-reactivity with other respiratory pathogens.
• Integration with Sofia® 2 Reader: The test is compatible with the Sofia® 2 Fluorescence Immunoassay Analyzer, an automated reader that provides objective and consistent results. The reader enhances test accuracy and reduces the potential for human error in result interpretation.
• Versatile Application: Suitable for use in a range of healthcare settings, including emergency departments, urgent care centers, and primary care practices. The test is also adaptable for use in mass screening and surveillance programs.
• CLIA Waived: The Sofia® 2 SARS Antigen FIA is CLIA waived for use in point-of-care settings, making it an ideal choice for rapid testing in environments with regulatory flexibility.